Vanguard Portfolio Management
MDGL icon

Vanguard Portfolio Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Vanguard Portfolio Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420M Sell
781,731
-59,414
-7% -$30.4M 0.02% 793
2026
Q1 		$440M Buy
+841,145
New +$402M 0.02% 717

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Portfolio Management's MDGL Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 7.1% in Q2 2026, selling an estimated $30.4M and leaving 781,731 shares worth $420M. The position accounts for 0.02% of the portfolio, ranked #793.

Vanguard Portfolio Management first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. The position peaked at $440M in Q1 2026. 402 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Vanguard Portfolio Management held 781,731 shares of Madrigal Pharmaceuticals worth $420M as of Q2 2026.
  • Vanguard Portfolio Management sold 59,414 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $30.4M.
  • Madrigal Pharmaceuticals made up 0.02% of Vanguard Portfolio Management's portfolio in Q2 2026, its #793 holding.
  • Vanguard Portfolio Management first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Madrigal Pharmaceuticals position peaked at $440M in Q1 2026.
  • 402 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.